Jason Karp, MD
Pulmonary Disease · Lake Success, NYNPI 1376514265
Payments from drug & device makers
Across 96 payments — averaging $560.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$31K
- Regeneron$16K
- Jazz Pharmaceuticals Inc.$1K
- Insmed, Inc.$928
- Amgen$721
- AstraZeneca$676
- plus $3K from 20 others
What the payments were for
- Consulting fees$1,52014%
- Speaking & faculty fees$3,85535%
- Food & beverage$5,52050%
- Education$2332%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 16 | $31,334 |
| Regeneron | 4 | $15,713 |
| Jazz Pharmaceuticals Inc. | 1 | $1,050 |
| Insmed, Inc. | 3 | $928 |
| Amgen | 6 | $721 |
| AstraZeneca | 7 | $676 |
| Philips North America LLC | 10 | $569 |
| Actelion Pharmaceuticals US, Inc. | 6 | $543 |
| Regeneron Healthcare Solutions, Inc. | 12 | $371 |
| Inspire Medical Systems, Inc. | 3 | $287 |
| Sanofi | 4 | $277 |
| Ventec Life Systems, Inc. | 2 | $220 |
| Genentech USA, Inc. | 5 | $200 |
| United Therapeutics Corporation | 2 | $140 |
| 3b Medical, Inc. | 1 | $135 |
| Pulmonx Corporation | 2 | $130 |
| Olympus America Inc. | 1 | $125 |
| Mallinckrodt Hospital Products Inc. | 2 | $124 |
| Intuitive Surgical | 1 | $72 |
| Medtronic | 1 | $50 |
| Genentech, Inc. | 2 | $33 |
| Bayer | 1 | $18 |
| Boehringer Ingelheim | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Pfizer | 1 | $11 |
| Sunovion Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$3,814
- SUNOSI$1,050
- Arikayce$925
- TEZSPIRE$716
- DUPIXENT$634
- inCourage$218
- Inspire Upper Airway Stimulation System$141
- LUNA$135
- UPTRAVI$115
- OPSYNVI$115
- CHARTIS CATHETER$112
- ZEPHYR DELIVERY CATHETER$112
- ZEPHYR ENDOBRONCHIAL VALVE$112
- PULMONX CHARTIS TABLET CONSOLE$112
- (AK6) Vest Therapy$109
- Inspire$108
How this compares
$53,770 in reported general payments places this provider in the 90th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,722 | $1,963,993 |
| OfevNintedanib Esylate | 103 | $1,593,668 |
| Dupixent PenDupilumab | 286 | $1,148,731 |
| OpsumitMacitentan | 82 | $1,048,173 |
| UptraviSelexipag | 34 | $861,704 |
| WinrevairSotatercept-Csrk | 31 | $614,056 |
| Breo ElliptaFluticasone/Vilanterol | 605 | $470,312 |
| NucalaMepolizumab | 102 | $396,902 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 353 | $365,876 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 324 | $292,997 |
| Spiriva RespimatTiotropium Bromide | 248 | $285,748 |
| AdempasRiociguat | 19 | $242,294 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 243 | $216,141 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 184 | $157,286 |
| Incruse ElliptaUmeclidinium Bromide | 216 | $140,683 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta | $31,334 | $3,351,3953,139 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $15 | $2,195,223697 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $543 | $1,909,877116 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort, Tezspire, Pulmicort Flexhaler | $676 | $767,334889 claims |
| BayerAdempas | $18 | $242,29419 claims |
| Genentech, Inc.Xolair | $33 | $123,66120 claims |
| Hikma Pharmaceuticals USARyaltris | $15 | $29,17278 claims |
| United Therapeutics CorporationAdcirca | $140 | $27,37518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Lake Success
- Lawrence ShulmanLake Success$228K
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
- Sherif El BayadiSyracuse$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.